Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-ND 4.0Nature Cardiovascular Research

Temporal proteomics maps concealed-stage remodeling and reveals early mitochondrial alteration as an intervention target in a model of PKP2-arrhythmogenic cardiomyopathy

  1. 1Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  2. 2The Leon H. Charney Division of Cardiology, NYU Grossman School of Medicine, New York, NY USA
  3. 3Diabetes Research Program, Holman Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, NYU Grossman School of Medicine, New York, NY USA

Abstract

Arrhythmogenic cardiomyopathy is a heritable cardiac disorder commonly linked to alterations in desmosomal proteins. While desmosomal dysfunction is a recognized pathogenic mechanism, the early molecular remodeling that precedes clinical manifestations remains unclear. Here we used a mouse model with inducible cardiomyocyte-specific knockout of Pkp2 (encoding plakophilin-2) and performed time-resolved mass spectrometry-based proteomics to map disease progression from early PKP2 loss to structural remodeling. Molecular changes preceded phenotypic abnormalities, and spatial asymmetry was evident, with earlier and more pronounced proteome remodeling in the right ventricle despite comparable PKP2 depletion in both ventricles. Downregulation of protein networks spanning desmosomes, sarcomeres and mitochondria suggests their functional coupling, with mitochondrial remodeling emerging as an early and progressively worsening feature. Intervention with honokiol attenuated changes across the major protein networks, highlighting mitochondrial pathways as promising therapeutic targets and honokiol as a potential strategy to delay arrhythmogenic cardiomyopathy progression. Our findings provide critical insights into the concealed stage of disease progression and identify molecular targets for early intervention.

Related

  1. Disease Stage and Efficacy Interpretation in Gene Therapy for Arrhythmogenic Cardiomyopathy
    Andrea Mazzanti
    Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseasePeer-reviewedCC BY-NC 4.0Full textCardiovascular medicinePMC
  2. Elimination of Epicardial Late Potentials by Endocardial Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy
    A Hermida, C Pavone, R Sauve +13
    EP-EuropacePeer-reviewedCC BYGeneral biologyCardiovascular medicineHAL
  3. Incremental prognostic value of hepatic tissue alterations derived from cardiac magnetic resonance imaging for arrhythmogenic right ventricular cardiomyopathy: a case-control study
    Xiahui Tian, Yuelong Yang, Guanyu Lu +8
    Quantitative imaging in medicine and surgeryPeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMC
  4. Risk Stratification and Outcomes of Right Atrial Phasic Function in Arrhythmogenic Right Ventricular Cardiomyopathy: A Cardiac Magnetic Resonance Study
    Wenqing Xu, Xuan Ma, Yanyan Song +12
    Journal of the American Heart AssociationPeer-reviewedLicence not statedCardiovascular medicineCrossref
  5. Clinical relevance of lead-induced tricuspid regurgitation after transvenous implantable cardioverter-defibrillator implantation in arrhythmogenic cardiomyopathy
    Federico Migliore, Raimondo Pittorru, Alberto Cipriani +11
    EuropacePeer-reviewedCC BY 4.0Full textCardiovascular medicinePMC
BibTeX
@article{achter2026temporal,
  title = {{Temporal proteomics maps concealed-stage remodeling and reveals early mitochondrial alteration as an intervention target in a model of PKP2-arrhythmogenic cardiomyopathy}},
  author = {Jonathan S. Achter and Mikkel Svenningsen and John Mulvey and Giorgia Bertoli and Emily Meyer and Gautam Yepuri and Mingliang Zhang and Ravichandran Ramasamy and Mario Delmar and Alicia Lundby},
  journal = {Nature Cardiovascular Research},
  year = {2026},
  month = oct,
  doi = {10.1038/s44161-026-00894-4},
  url = {https://doi.org/10.1038/s44161-026-00894-4},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Temporal proteomics maps concealed-stage remodeling and reveals early mitochondrial alteration as an intervention target in a model of PKP2-arrhythmogenic cardiomyopathy
AU  - Jonathan S. Achter
AU  - Mikkel Svenningsen
AU  - John Mulvey
AU  - Giorgia Bertoli
AU  - Emily Meyer
AU  - Gautam Yepuri
AU  - Mingliang Zhang
AU  - Ravichandran Ramasamy
AU  - Mario Delmar
AU  - Alicia Lundby
PY  - 2026
DA  - 2026/10/29
JO  - Nature Cardiovascular Research
DO  - 10.1038/s44161-026-00894-4
UR  - https://doi.org/10.1038/s44161-026-00894-4
AB  - Arrhythmogenic cardiomyopathy is a heritable cardiac disorder commonly linked to alterations in desmosomal proteins. While desmosomal dysfunction is a recognized pathogenic mechanism, the early molecular remodeling that precedes clinical manifestations remains unclear. Here we used a mouse model with inducible cardiomyocyte-specific knockout of Pkp2 (encoding plakophilin-2) and performed time-resolved mass spectrometry-based proteomics to map disease progression from early PKP2 loss to structural remodeling. Molecular changes preceded phenotypic abnormalities, and spatial asymmetry was evident, with earlier and more pronounced proteome remodeling in the right ventricle despite comparable PKP2 depletion in both ventricles. Downregulation of protein networks spanning desmosomes, sarcomeres and mitochondria suggests their functional coupling, with mitochondrial remodeling emerging as an early and progressively worsening feature. Intervention with honokiol attenuated changes across the major protein networks, highlighting mitochondrial pathways as promising therapeutic targets and honokiol as a potential strategy to delay arrhythmogenic cardiomyopathy progression. Our findings provide critical insights into the concealed stage of disease progression and identify molecular targets for early intervention.
SN  - 2731-0590
ER  -